AGTX (Agentix) OCF Margin %: 0.00% (As of Dec. 2025)


What is Agentix OCF Margin %?

Agentix AGTX OCF Margin % is 0.00% as of Dec. 2025. The stock has 3 warning signs investors should review. Among 959 Biotechnology companies, Agentix ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Agentix's Cash Flow from Operations for the three months ended in Dec. 2025 was $-0.01 Mil. Agentix's Revenue for the three months ended in Dec. 2025 was $0.00 Mil. Therefore, Agentix's OCF Margin % for the quarter that ended in Dec. 2025 was 0.00%.

As of today, Agentix's current OCF Yield % is -16.57%.

The historical rank and industry rank for Agentix's OCF Margin % or its related term are showing as below:


During the past 11 years, the highest OCF Margin % of Agentix was -30.23%. The lowest was -42100.00%. And the median was -2233.93%.

AGTX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Agentix OCF Margin % Related Terms

Agentix OCF Margin % Historical Data

* Premium members only.

The historical data trend for Agentix's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Agentix OCF Margin % Chart

Agentix Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Mar23 Mar24 Mar25
OCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -42,100.00 0.00 0.00 0.00

Agentix Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Agentix OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Agentix's OCF Margin for the fiscal year that ended in Mar. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Mar. 2025 )/Revenue (A: Mar. 2025 )
=-0.125/0
= %

Agentix's OCF Margin for the quarter that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-0.008/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Agentix (AGTX) has a OCF Margin % of 0.00% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Agentix and its competitors. According to the industry distribution chart, Agentix ranks #999999 out of 959 companies in the Biotechnology industry.
Is Agentix's OCF Margin % too high?
Agentix's current OCF Margin % is 0.00%. Based on the distribution chart, Agentix ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Agentix's OCF Margin % compare to CERO and EVFM?
According to the Biotechnology industry distribution chart, Agentix ranks #999999 out of 959 companies for OCF Margin %. This places Agentix in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Agentix and its competitors. Agentix's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agentix stock overvalued right now?
Agentix (AGTX) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Agentix (AGTX), the current OCF Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Agentix Business Description

Address 32932 Pacific Coast Highway, No. 14-254, Dana Point, CA, USA, 92629
Agentix Corp is a biotechnology company. Through its subsidiary, it is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space. Its pipeline of drug candidates includes AGTX-2004, a CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM), and AGTX-2003 a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease.